Alvotech SA
ALVO8.890USD
+0.100+1.14%
交易中 （美东）报价延迟15分钟
2.68B总市值
27.79市盈率 TTM
关于 Alvotech SA 公司
Alvotech SA 是一家生物技术公司。该公司专注于为全球患者开发和生产生物仿制药。该公司致力于开发一系列单克隆抗体，这些抗体针对多种治疗领域，包括炎症性疾病、肿瘤学和眼科。该公司的产品线包含八种生物仿制药候选药物，旨在治疗自身免疫性疾病、眼部疾病、骨质疏松症、呼吸系统疾病和癌症。其产品线包括 AVT02、AVT04、AVT23、AVT03、AVT05、AVT06、AVT16 和 AVT33。其 AVT02 是一种单克隆抗体，是 Humira（阿达木单抗）的生物仿制药。AVT04 是一种单克隆抗体，是 Stelara（乌司奴单抗）的生物仿制药候选药物。它已形成一个战略商业合作伙伴网络，提供全球覆盖范围并利用包括美国、欧洲、日本、中国和其他亚洲国家以及南美洲、非洲和中东大部分地区的市场的专业知识。
公司简介
公司代码ALVO
公司名称Alvotech SA
上市日期Nov 09, 2020
CEOMr. Robert (Vilhelm) Wessman
员工数量1011
证券类型Ordinary Share
年结日Nov 09
公司地址9, Rue De Bitbourg
城市LUXEMBOURG
上市交易所NASDAQ Global Market Consolidated
国家Luxembourg
邮编1273
电话35244224500
网址https://www.alvotech.com/
公司代码ALVO
上市日期Nov 09, 2020
CEOMr. Robert (Vilhelm) Wessman
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
Mr. Benedikt Stefansson
Mr. Benedikt Stefansson
Director of Investor Relations and Global Communications
Director of Investor Relations and Global Communications
--
--
Ms. Tanya Zharov
Ms. Tanya Zharov
General Counsel
General Counsel
--
--
Mr. Faysal Kalmoua
Mr. Faysal Kalmoua
Chief Operating Officer, Executive Director
Chief Operating Officer, Executive Director
--
--
Mr. Tomas Ekman
Mr. Tomas Ekman
Non-Executive Independent Director
Non-Executive Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard John Davies
Mr. Richard John Davies
Non-Executive Independent Deputy Chairman of the Board
Non-Executive Independent Deputy Chairman of the Board
1.07M
+1.88%
Ms. Lisa Graver, J.D.
Ms. Lisa Graver, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Ms. Ann Merchant
Ms. Ann Merchant
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Dr. Linda Mcgoldrick, Ph.D.
Dr. Linda Mcgoldrick, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
21.16K
+100.00%
Mr. Hjoerleifur Palsson
Mr. Hjoerleifur Palsson
Non-Executive Independent Director
Non-Executive Independent Director
2.35K
--
Mr. Uri Hillel
Mr. Uri Hillel
Chief Quality Officer
Chief Quality Officer
--
--
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2024
FY2023
FY2022
暂无数据
地区USD
名称
营收
占比
USA
273.04M
55.76%
Europe
157.59M
32.18%
Rest of the world
59.06M
12.06%
业务
地区
暂无数据
股东统计
更新时间: 5月26日 周一
更新时间: 5月26日 周一
持股股东
股东类型
持股股东
持股股东
占比
Aztiq Pharma Partners SARL
33.33%
Celtic Holdings SCA
29.66%
The Vanguard Group, Inc.
1.38%
Bracebridge Capital, LLC
0.89%
Oaktree Capital Management, L.P.
0.65%
Other
34.09%
持股股东
持股股东
占比
Aztiq Pharma Partners SARL
33.33%
Celtic Holdings SCA
29.66%
The Vanguard Group, Inc.
1.38%
Bracebridge Capital, LLC
0.89%
Oaktree Capital Management, L.P.
0.65%
Other
34.09%
股东类型
持股股东
占比
Corporation
62.99%
Investment Advisor
2.33%
Investment Advisor/Hedge Fund
1.94%
Hedge Fund
1.40%
Individual Investor
0.46%
Private Equity
0.43%
Research Firm
0.34%
Other
30.11%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
114
212.07M
69.88%
-4.61M
2025Q1
115
212.60M
70.06%
-4.31M
2024Q4
102
214.30M
71.08%
-114.96K
2024Q3
87
213.88M
70.94%
+661.45K
2024Q2
85
209.20M
73.73%
-4.01M
2024Q1
143
208.53M
73.94%
-24.07M
2023Q4
136
211.95M
80.98%
-21.83M
2023Q3
145
212.41M
81.19%
-22.41M
2023Q2
144
212.79M
81.57%
-23.47M
2023Q1
154
213.81M
82.04%
-23.18M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Aztiq Pharma Partners SARL
101.15M
33.33%
-2.59M
-2.49%
Mar 01, 2025
Celtic Holdings SCA
90.01M
29.66%
--
--
Mar 01, 2025
The Vanguard Group, Inc.
4.19M
1.38%
+995.54K
+31.14%
Mar 31, 2025
Bracebridge Capital, LLC
2.71M
0.89%
--
--
Mar 31, 2025
Oaktree Capital Management, L.P.
1.97M
0.65%
-68.40K
-3.35%
Mar 31, 2025
T. Rowe Price International Ltd
1.40M
0.46%
+1.20M
+587.57%
Mar 31, 2025
Littlejohn & Co. LLC
1.32M
0.43%
--
--
Mar 31, 2025
PointState Capital LP
1.17M
0.39%
-67.04K
-5.40%
Mar 31, 2025
Davies (Richard John)
1.07M
0.35%
+19.71K
+1.88%
Mar 01, 2025
Stefnir hf.
998.47K
0.33%
-10.00K
-0.99%
May 31, 2025
查看更多
持股ETF
更新时间: 8月2日 周六
更新时间: 8月2日 周六
机构名称
占比
ProShares Ultra Nasdaq Biotechnology
0.27%
Invesco Nasdaq Biotechnology ETF
0.27%
iShares Biotechnology ETF
0.1%
Strive Small-Cap ETF
0.04%
Schwab Emerging Markets Equity ETF
0.01%
Fidelity Nasdaq Composite Index ETF
0.01%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
Vanguard Total World Stock Index Fund
0%
First Trust IPOX Europe Equity Opportunities ETF
0%
Vanguard FTSE All-World ex-US Index Fund
0%
ProShares Ultra Nasdaq Biotechnology
占比0.27%
Invesco Nasdaq Biotechnology ETF
占比0.27%
iShares Biotechnology ETF
占比0.1%
Strive Small-Cap ETF
占比0.04%
Schwab Emerging Markets Equity ETF
占比0.01%
Fidelity Nasdaq Composite Index ETF
占比0.01%
Invesco RAFI US 1500 Small-Mid ETF
占比0.01%
Vanguard Total World Stock Index Fund
占比0%
First Trust IPOX Europe Equity Opportunities ETF
占比0%
Vanguard FTSE All-World ex-US Index Fund
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
